Company intelligence / Profile preview

YnnoMed

Hong Kong, Hong Kong

Ownership: Private
Development stage: Other

Overview

YnnoMed is conducting pre-clinical development for several first-in-class small molecule antibacterial candidates that inhibit bacterial transcription, with proven in vitro effectiveness against WHO priority drug-resistant pathogens; IND-enabling activities are underway with clinical trials anticipated in ~1-2 years

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Hong Kong Science and Technology Parks Corporation (HKSTP)Shanghai Pharmaceuticals Holding Co., Ltd. (SPH) Co-incubation ProgrammeShanghai Healthcare Capital (SHC)The Hong Kong Polytechnic UniversityThe Chinese University of Hong Kong

Beyond the preview

Go deeper on YnnoMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YnnoMed.

Explore the full profile